SI-BONE, Inc. - Common Stock (SIBN)

Take-up of the company's wares among physicians is rising significantly.

SI-BONE (SIBN) beats Q3 2025 earnings and revenue estimates, prompting a stock surge and an upward revision to its full-year guidance.

In a significant move to avert a potential financial crisis, the Federal Reserve announced in October 2025 its decision to halt its three-year Quantitative Tightening (QT) program and cut interest rates. This decisive action comes amidst growing concerns over tightening liquidity in money markets and recent market strains, signaling that

SI-BONE INC reports mixed Q2 2025 results with revenue slightly below estimates but beats on EPS, driving a positive market reaction. Strong growth and raised guidance signal confidence.

Four companies experienced significant short-term rallies following better-than-expected earnings; can they maintain momentum going forward?